

WHAT IS CLAIMED IS:

1. A formulation comprising at least one hybridoma having at least one first cell fused to at least one second cell; wherein said first cell is an antigen presenting cell selected from the group consisting of a macrophage and a dendritic cell, and said second cell is selected from the group consisting of a tumor cell and a virally infected cell.
2. The formulation of Claim 1, wherein said dendritic cells are selected from the group consisting of cutaneous epidermal Langerhans cells, dermal dendritic cells, lymph node dendritic cells, spleen dendritic cells and dendritic cells derived through *in vitro* culture of precursors.
3. The formulation of Claim 1, wherein said tumor cells are selected from the group consisting of melanoma cells, lung carcinoma cells, sarcomas, prostate carcinoma cells, breast carcinoma cells, colon carcinoma cells and cervical carcinoma cells.
4. The formulation of Claim 1, wherein said virally infected cells are selected from the group consisting of cells infected with influenza virus, human immunodeficiency virus, cytomegalo virus, human papilloma virus and herpes simplex virus.
5. The formulation of Claim 1, wherein said hybridoma contains a ratio of first cells to second cells between about 1:100 and 100:1.
6. The formulation of Claim 1, wherein said hybridoma contains a ratio of first cells to second cells of between about 1:10 and 10:1.
7. The formulation of Claim 1, wherein said hybridoma contains a ratio of first cells to second cells of about 6:1.

09864451-052501

8. A pharmaceutical composition comprising:
at least one hybridoma; and
a suitable pharmaceutical carrier;
wherein each hybridoma is comprised of at least one first cell
fused to at least one second cell;

wherein said first cell is an antigen presenting cell selected
from the group consisting of a macrophage and a dendritic cell, and said second cell
is selected from the group consisting of a tumor cell and a virally infected cell.

9. The pharmaceutical composition of Claim 8, wherein said
suitable pharmaceutical carrier is selected from the group consisting of saline and
phosphate buffered saline.

10. The pharmaceutical composition of Claim 8, wherein said
hybridomas have a ratio of first cells to second cells of between about 1:100 and
100:1.

11. The pharmaceutical composition of Claim 8, wherein said
hybridomas have a ratio of first cells to second cells of between about 1:10 and
10:1.

12. The pharmaceutical composition of Claim 9, wherein said
hybridomas have a ratio of first cells to second cells of about 6:1.

13. A formulation comprising the products of co-cultures of a
plurality of first cells and a plurality of second cells; wherein said first cells are
antigen presenting cells selected from the group consisting of macrophages, B-cells
and dendritic cells, and said second cells are selected from the group consisting of
tumor cells and virally infected cells.

14. The formulation of Claim 13, wherein said dendritic cells are
selected from the group consisting of cutaneous epidermal Langerhans cells, dermal
dendritic cells, lymph node dendritic cells, spleen dendritic cells and dendritic cells
derived through *in vitro* culture of precursors.

15. The formulation of Claim 13, wherein said tumor cells are
selected from the group consisting of melanoma cells, lung carcinoma cells,
sarcomas, prostate carcinoma cells, breast carcinoma cells, colon carcinoma cells
and cervical carcinoma cells.

09864451.052501

A

16. The formulation of Claim 13, wherein said virally infected cells are selected from the group consisting of cells infected with influenza virus, human immunodeficiency virus, cytomegalo virus, human papilloma virus and herpes simplex virus.

17. The formulation of Claim 13, wherein said co-culture has a ratio of first cells to second cells of between about 1:100 and 100:1.

18. The formulation of Claim 13, wherein said co-culture has a ratio of first cells to second cells of between about 1:10 and 10:1.

19. The formulation of Claim 13, wherein said co-culture has a ratio of first cells to second cells of about 6:1.

20. A pharmaceutical composition comprising:
the products of co-cultures of a plurality of first cells and a plurality of second cells; and
a suitable pharmaceutical carrier;
wherein said first cells are antigen presenting cells selected from the group consisting of macrophages, B-cells and dendritic cells, and said second cells are selected from the group consisting of tumor cells and virally infected cells.

21. The pharmaceutical composition of Claim 20, wherein the suitable pharmaceutical carrier is selected from the group consisting of saline and phosphate buffered saline.

22. The pharmaceutical composition of Claim 20, wherein said co-culture has a ratio of first cells to second cells of between about 1:100 and 100:1.

23. The pharmaceutical composition of Claim 20, wherein said co-culture has a ratio of first cells to second cells of between about 1:10 and 10:1.

24. The pharmaceutical composition of Claim 20, wherein said co-culture has a ratio of first cells to second cells of about 6:1.

25. A method for treating a patient comprising:
administering to said patient an effective amount of a formulation comprising at least one hybridoma having at least one first cell fused to at least one second cell; wherein said first cell is an antigen presenting cell selected from the group consisting of a macrophage and a dendritic cell, and said second cell is selected from the group consisting of a tumor cell and a virally infected cell; and

09864451.052501

wherein said administration results in stimulation of a CTL response.

26. The method of Claim 25, wherein said dendritic cells are selected from the group consisting of cutaneous epidermal Langerhans cells, dermal dendritic cells, lymph node dendritic cells, spleen dendritic cells and dendritic cells derived through *in vitro* culture of precursors.

27. The method of Claim 25, wherein said tumor cells are selected from the group consisting of melanoma cells, lung carcinoma cells, sarcomas, prostate carcinoma cells, breast carcinoma cells, colon carcinoma cells and cervical carcinoma cells.

28. The method of Claim 25, wherein said virally infected cells are selected from the group consisting of cells infected with influenza virus, human immunodeficiency virus, cytomegalo virus, human papilloma virus and herpes simplex virus.

29. The method of Claim 25, wherein said formulation further comprises a suitable pharmaceutical carrier.

30. The method of Claim 25, wherein said effective amount is between about 1×10^6 and 100×10^6 cells.

31. A method for treating a patient comprising:
administering to said patient an effective amount of a formulation comprising the products of co-culture of a plurality of first cells and a plurality of second cells; wherein said first cells are antigen presenting cells selected from the group consisting of macrophages, B-cells and dendritic cells, and said second cells are selected from the group consisting of tumor cells and virally infected cells; and

wherein said administration results in stimulation of a CTL response.

32. The method of Claim 31, wherein said dendritic cells are selected from the group consisting of cutaneous epidermal Langerhans cells, dermal dendritic cells, lymph node dendritic cells, spleen dendritic cells and dendritic cells derived through *in vitro* culture of precursors.

33. The method of Claim 31, wherein said tumor cells are selected from the group consisting of melanoma cells, lung carcinoma cells,

00864451-052501

sarcomas, prostate carcinoma cells, breast carcinoma cells, colon carcinoma cells and cervical carcinoma cells.

34. The method of Claim 31, wherein said virally infected cells are selected from the group consisting of cells infected with influenza virus, human immunodeficiency virus, cytomegalo virus, human papilloma virus and herpes simplex virus.

35. The method of Claim 31, wherein said formulation further comprises a suitable pharmaceutical carrier.

36. The method of Claim 31, wherein said effective amount is between about 1×10^6 and 100×10^6 cells.

0964451-052501
FOI 250 "TS-119860"